[go: up one dir, main page]

WO2008009894A3 - Use of imino sugars in immunotherapy - Google Patents

Use of imino sugars in immunotherapy Download PDF

Info

Publication number
WO2008009894A3
WO2008009894A3 PCT/GB2007/002597 GB2007002597W WO2008009894A3 WO 2008009894 A3 WO2008009894 A3 WO 2008009894A3 GB 2007002597 W GB2007002597 W GB 2007002597W WO 2008009894 A3 WO2008009894 A3 WO 2008009894A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune system
immunotherapy
prr
immunoprophylaxis
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/002597
Other languages
French (fr)
Other versions
WO2008009894A2 (en
Inventor
Robert James Nash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit Therapeutics Ltd
Original Assignee
Summit Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp PLC filed Critical Summit Corp PLC
Publication of WO2008009894A2 publication Critical patent/WO2008009894A2/en
Publication of WO2008009894A3 publication Critical patent/WO2008009894A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Described are uses for various imino sugars in PRR-mediated immunotherapy or immunoprophylaxis. In particular, the invention relates to the use of imino sugar PRR (particularly C-type lectin) ligands in immune response variegation and/or the stimulation of immune surveillance (for example by the innate immune system) and/or non-specific immunoprophylaxis. The invention therefore finds application in the treatment of pathological variegated states (for example those arising from pathogen-mediated immune system subversion or immune system dysfunction) and for inhibiting or postponing neutrophil apoptosis.
PCT/GB2007/002597 2006-07-15 2007-07-12 Use of imino sugars in immunotherapy Ceased WO2008009894A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0614098.2A GB0614098D0 (en) 2006-07-15 2006-07-15 Immune response variegation with imino sugars
GB0614098.2 2006-07-15

Publications (2)

Publication Number Publication Date
WO2008009894A2 WO2008009894A2 (en) 2008-01-24
WO2008009894A3 true WO2008009894A3 (en) 2008-06-19

Family

ID=36955728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002597 Ceased WO2008009894A2 (en) 2006-07-15 2007-07-12 Use of imino sugars in immunotherapy

Country Status (2)

Country Link
GB (1) GB0614098D0 (en)
WO (1) WO2008009894A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102659787B (en) * 2011-03-29 2015-04-01 中国科学院化学研究所 Fluoro polyhydroxy pyrrole pyrrolizidine, and preparation method and application thereof
CN109843327B (en) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 Antibody adjuvant conjugates
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
WO2001068093A1 (en) * 2000-03-17 2001-09-20 Oxford Glycosciences (Uk) Limited Use of glucosylceramide synthesis inhibitors in brain cancertherapy
US20040110795A1 (en) * 1999-08-10 2004-06-10 United Therapeutics Corp. Use of iminosugar derivatives to inhibit ion channel activity
WO2005039578A2 (en) * 2003-10-29 2005-05-06 Macrozyme B.V. Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
WO2005070418A1 (en) * 2004-01-21 2005-08-04 M N L Pharma Limited Immunomodulatory alkaloids
WO2006077427A2 (en) * 2005-01-21 2006-07-27 Mnl Pharma Limited Antiviral drug combinations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US20040110795A1 (en) * 1999-08-10 2004-06-10 United Therapeutics Corp. Use of iminosugar derivatives to inhibit ion channel activity
WO2001068093A1 (en) * 2000-03-17 2001-09-20 Oxford Glycosciences (Uk) Limited Use of glucosylceramide synthesis inhibitors in brain cancertherapy
WO2005039578A2 (en) * 2003-10-29 2005-05-06 Macrozyme B.V. Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
WO2005070418A1 (en) * 2004-01-21 2005-08-04 M N L Pharma Limited Immunomodulatory alkaloids
WO2006077427A2 (en) * 2005-01-21 2006-07-27 Mnl Pharma Limited Antiviral drug combinations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DE CLERCQ ERIK: "Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, no. 14, 1995, pages 2491 - 2517, XP002387020, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
GB0614098D0 (en) 2006-08-23
WO2008009894A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
TWI365939B (en) Fluid system having multiple pump chambers
MX277615B (en) Method of preparing microfibrillar polysaccharide.
WO2005089483A3 (en) Low glycemic sweeteners and products made using the same
WO2006063302A3 (en) Variants of glycogen synthase kinase 3 and uses thereof
WO2007059041A3 (en) Combinations and methods of using an immunomodulatory oligodeoxynucleotide
WO2008029096A3 (en) P53 activating benzoyl urea and benzoyl thiourea compounds
WO2008151807A3 (en) Heat-stable asparaginase for reducing acrylamide in foodstuffs or stimulants
IL185189A0 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2009155001A3 (en) Wnt protein signalling inhibitors
WO2008119527A3 (en) Agonists of bitter taste receptors and uses thereof
WO2009052431A3 (en) Cd19 binding agents and uses thereof
WO2009055427A3 (en) Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
WO2009055669A3 (en) Monoclonal antibodies against activated and unactivated protein c
WO2010102052A3 (en) Methods of inhibiting photoreceptor apoptosis
WO2007092496A3 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2014036040A3 (en) Methods for diagnosis, prognosis and methods of treatment
WO2018126278A3 (en) Methods to distinguish rna and dna in a combined preparation
ZA200806922B (en) Delay elements, detonators containing the same and methods of making
WO2014036528A3 (en) Agents useful for treating obesity, diabetes and related disorders
BR112019001602A2 (en) sugar composition
WO2009085269A3 (en) Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
WO2008009894A3 (en) Use of imino sugars in immunotherapy
WO2007146813A3 (en) Pyridinone analogs as cell proliferation inhibitors
AP2247A (en) Extraction of metal from metal ore.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766185

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07766185

Country of ref document: EP

Kind code of ref document: A2